Upcoming Special Issue Releases-Journal Drug Designing: Open Access

Drug Design in the context of the Cancer: Recent advance

Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. Approximately 70% of deaths from cancer occur in low- and middle-income countries. Cancer is a leading cause of death worldwide, accounting for an estimated 9.6 million deaths in 2018.

Acknowledging the current situation regarding covid-19 and cancer research, Drug Designing: Open Access Journal is coming up with a special issue titled: “Drug Design in the context of the Cancer: Recent advance” which has been edited by Dr. Gjumrakch Aliev.

Dr. Gjumrakch Aliev is the President and CEO of GALLY International Biomedical Research Consulting LLC, San Antonio, USA. He has a vast scope and experience as medical researcher on cancer.

We warmly and enthusiastically invite the eminent researchers to take part in this special issue to enhance recent advancements in cancer research.

We encourage submission of research articles, review articles, short communication, mini-review, case reports, editorial, etc. through email at drugdesign[at]eclinicalsci[dot]org

The submission deadline is November 25th, 2020.

Drug Design in the Context of the Neurodegenerative diseases

The brain is an extremely complex organ with vast numbers of pathways that allow us to do the amazing things that we do. Neurodegenerative Diseases are Brain illness that causes neurons to die and the brain to shrink. People all over the world are suffering from neurodegenerative diseases, which are illnesses that lead to cell death in the brain.

Acknowledging the current situation regarding Neurodegenerative Diseases Research, Drug Designing: Open Access Journal is coming up with a special issue titled: “Drug Design in the Context of the Neurodegenerative diseases” which has been edited by Dr. Gjumrakch Aliev.

Dr. Gjumrakch Aliev is the President and CEO of GALLY International Biomedical Research Consulting LLC, San Antonio, USA. He has a vast scope and experience on Biomedical Research.

We warmly and enthusiastically invite the eminent researchers to take part in this special issue to enhance recent advancements in Neurodegenerative diseases.

We encourage submission of research articles, review articles, short communication, mini-review, case reports, editorial, etc. through email at drugdesign[at]eclinicalsci[dot]org

The submission deadline is November 25th, 2020.

Study, Design, Analysis of Clinical Trails

Most countries have adopted the good clinical practice (GCP) principles as laws and regulations for approving clinical trials which are conducted to test new methods to prevent, detect, and treat disease or drug development. Most regulatory agencies such as the United State Food and Drug Administration (FDA) indicate that only adequate and well-controlled clinical trials can provide substantial evidence of safety and effectiveness of the test treatment under investigation.

Study, Design and Analysis of Clinical Trials provides complete, comprehensive, and expanded coverage of recent health treatments and interventions, In this context Drug Designing: Open Access Journal is coming up with a special issue titled: “Study, Design, Analysis of Clinical Trails” which has been edited by Dr. Shein-Chung Chow.

Dr. Shein-Chung Chow, PhD, is Professor in the Department of Biostatistics and Bioinformatics at Duke University School of Medicine, United States. He has authored multiple articles and books on clinical trials and been involved in clinical trials as a biostatistician.

We warmly and enthusiastically invite the eminent researchers to take part in this special issue to enhance recent Study, Design and Analysis of Clinical Trials.

We encourage submission of research articles, review articles, short communication, mini-review, case reports, editorial, etc. through email at drugdesign[at]eclinicalsci[dot]org

The submission deadline is December 15th, 2020.  

Drug Designing: Open Access Journal is using Editorial Tracking System to maintain quality and transparency to the author in the peer-review process. Review processing will be performed by the editorial board members of the Journal Drug Designing: Open Access or by Reviewers (outside experts in the field). Two independent reviewer’s approval (Minimum reviewer’s approval) followed by editor approval is obligatory for acceptance of any manuscript excluding an editorial.

Editorial tracking submission: https://www.longdom.org/submissions/drug-designing-open-access.html

Nancy Ella
Editor Board
Drug Designing: Open Access
drugdesign@eclinicalsci.org